A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment.

ABSTRACT:

Background

Human deciduous pulp stem cells (hDPSCs) have remarkable stem cell potency associated with cell proliferation, mesenchymal multipotency, and immunosuppressive function and have shown beneficial effects in a variety of animal disease models. Recent studies demonstrated that hDPSCs exhibited in vivo anti-fibrotic and anti-inflammatory action and in vivo hepatogenic-associated liver regeneration, suggesting that hDPSCs may offer a promising source with great clinical demand for treating liver diseases. However, how to manufacture ex vivo large-scale clinical-grade hDPSCs with the appropriate quality, safety, and preclinical efficacy assurances remains unclear.

Methods

We isolated hDPSCs from human deciduous dental pulp tissues formed by the colony-forming unit-fibrob

SUBMITTER: Iwanaka T 

PROVIDER: S-EPMC7093986 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature